Abound Financial LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Abound Financial LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,605 shares of the medical research company’s stock, valued at approximately $512,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. FMR LLC boosted its holdings in IQVIA by 38.7% in the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Impax Asset Management Group plc boosted its stake in shares of IQVIA by 9.7% during the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock worth $423,885,000 after acquiring an additional 157,809 shares during the last quarter. Nordea Investment Management AB boosted its stake in shares of IQVIA by 47.4% during the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of IQVIA by 3.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,226,083 shares of the medical research company’s stock worth $290,545,000 after acquiring an additional 39,772 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft dropped their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Stifel Nicolaus dropped their price target on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Bank of America dropped their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, BTIG Research downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Stock Performance

Shares of NYSE IQV opened at $190.94 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The company has a market cap of $33.62 billion, a P/E ratio of 25.46, a P/E/G ratio of 1.99 and a beta of 1.48. The firm’s fifty day moving average is $199.57 and its two-hundred day moving average is $216.34. IQVIA Holdings Inc. has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Insiders Place Their Bets

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at approximately $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.